Portfolio news .

MBS2320 administered to participants with moderate-to-severe Rheumatoid Arthritis

Istesso Limited, the immunometabolism drug discovery and development company, today announces the initiation of IST-06. This is a phase 2b randomized, multi-centre, double-blind parallel group, placebo-controlled trial investigating the efficacy and safety of multiple doses of the metabolic reprogramming agent MBS2320.

MBS2320 is a first-in-class investigational drug which reduces inflammation and supports the remodelling of damaged tissue. This dual mode-of-action enables MBS2320 to offer the unique potential to reverse underlying pathology in bone and joints.

The study will enrol patients with Rheumatoid Arthritis who have had an inadequate response to methotrexate. The primary endpoint is the proportion of subjects achieving American College of Rheumatology 20% (ACR20).

The study will consist of a twelve-week treatment period and will enrol subjects in multiple countries in Europe and Latin-America. Istesso expects results from the study in 2024.

Rheumatoid Arthritis is a chronic, progressive, and disabling auto-immune disease affecting one per cent of the global population, 165 million people worldwide.

Dr Lisa Patel, CEO and co-founder of Istesso comments: “This is a very exciting stage in the development of MBS2320, which we hope, in time, will help to transform the treatment of autoimmune diseases and create genuine improvements in patients’ health and quality of life”.

 

-ends-

For more information or to arrange an interview with an Istesso spokesperson, please contact Claire Fry, [email protected] / 01935 816 400

Notes to editors

Istesso is a clinical-stage biopharmaceutical company, developing novel drug candidates which reprogramme immune cell metabolism to treat autoimmune and inflammatory conditions. Istesso’s products have applications in conditions such as Rheumatoid Arthritis, Multiple Sclerosis and Cancer.

About MBS2320

MBS2320 is an investigational, first-in-class metabolic reprogramming agent. Its unique dual mode of action, reducing inflammation and supporting the remodelling of tissue damage gives MBS2320 the potential to both control the disease symptoms and resolve the underlying pathology across multiple disease indications including RA and other autoimmune diseases.

About rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic, progressive, and disabling auto-immune disease affecting one per cent of the global population, or ~165 million people worldwide. Unchecked, RA can progress very rapidly, causing swelling and damaging cartilage and bone around the joints and cause severe disability. A number of treatments are available for the conditions, but these are associated with increased infection rates, and for some classes, a risk of major cardiovascular events. In addition, a large proportion of patients fail to respond, or experience ongoing symptoms such as pain and flare, and continue to suffer from bone erosions.